Gerry McKenzie

Corporate Officer/Principal at AERIE PHARMACEUTICALS, INC.

Health Technology

Profile

Gerry McKenzie is currently the Vice President-Commercial Operations at Aerie Pharmaceuticals, Inc. He previously worked as the Chief Information Officer at AEON Biopharma Sub, Inc.

Gerry McKenzie active positions

Companies	Position	Start
AERIE PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

All active positions of Gerry McKenzie

Former positions of Gerry McKenzie

Companies	Position	End
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Chief Tech/Sci/R&D Officer	-

See the detail of Gerry McKenzie's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Gerry McKenzie's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX.	Health Technology
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Health Technology